AU2018249552A1 - Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety - Google Patents

Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety Download PDF

Info

Publication number
AU2018249552A1
AU2018249552A1 AU2018249552A AU2018249552A AU2018249552A1 AU 2018249552 A1 AU2018249552 A1 AU 2018249552A1 AU 2018249552 A AU2018249552 A AU 2018249552A AU 2018249552 A AU2018249552 A AU 2018249552A AU 2018249552 A1 AU2018249552 A1 AU 2018249552A1
Authority
AU
Australia
Prior art keywords
antimicrobial
pharmaceutical composition
synthetic cationic
antimicrobial pharmaceutical
cationic polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018249552A
Other languages
English (en)
Inventor
Michael P. Bevilacqua
Daniel J. HUANG
Doug LOOKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicrobe Inc
Original Assignee
Amicrobe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicrobe Inc filed Critical Amicrobe Inc
Publication of AU2018249552A1 publication Critical patent/AU2018249552A1/en
Priority to AU2023202283A priority Critical patent/AU2023202283B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
AU2018249552A 2017-04-06 2018-04-05 Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety Abandoned AU2018249552A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202283A AU2023202283B2 (en) 2017-04-06 2023-04-13 Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482630P 2017-04-06 2017-04-06
US62/482,630 2017-04-06
PCT/US2018/026322 WO2018187617A1 (en) 2017-04-06 2018-04-05 Compositions and uses of locally applied antimicrobials with enhanced performance and safety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202283A Division AU2023202283B2 (en) 2017-04-06 2023-04-13 Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety

Publications (1)

Publication Number Publication Date
AU2018249552A1 true AU2018249552A1 (en) 2019-10-31

Family

ID=63712780

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018249552A Abandoned AU2018249552A1 (en) 2017-04-06 2018-04-05 Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
AU2023202283A Active AU2023202283B2 (en) 2017-04-06 2023-04-13 Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202283A Active AU2023202283B2 (en) 2017-04-06 2023-04-13 Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety

Country Status (11)

Country Link
US (3) US11285189B2 (cg-RX-API-DMAC7.html)
EP (1) EP3606543A4 (cg-RX-API-DMAC7.html)
JP (3) JP2020513016A (cg-RX-API-DMAC7.html)
KR (2) KR20200018400A (cg-RX-API-DMAC7.html)
CN (1) CN110740744A (cg-RX-API-DMAC7.html)
AU (2) AU2018249552A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020781A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058901C (cg-RX-API-DMAC7.html)
MX (2) MX393548B (cg-RX-API-DMAC7.html)
SG (1) SG11201909016TA (cg-RX-API-DMAC7.html)
WO (1) WO2018187617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344635B (es) 2012-03-23 2017-01-04 Amicrobe Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
CN110740744A (zh) 2017-04-06 2020-01-31 艾麦克罗比公司 性能和安全性增强的局部施用的抗微生物剂的组合物和应用
JP2023501385A (ja) * 2019-11-08 2023-01-18 ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 抗微生物ペプチドを含む組成物
CN115397454A (zh) * 2020-03-31 2022-11-25 立美基股份有限公司 通过辐照对自组装肽进行灭菌
WO2021207164A1 (en) * 2020-04-08 2021-10-14 Amicrobe, Inc. Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections
WO2026060306A1 (en) * 2024-09-13 2026-03-19 Macro Biologics, Inc. Compositions and uses of locally applied synthetic cationic and hydrophobic amino acid block copolymers, for prevention and treatment of bacterial and fungal infections

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5636643A (en) 1991-11-14 1997-06-10 Wake Forest University Wound treatment employing reduced pressure
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6680365B1 (en) 1998-03-19 2004-01-20 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US20030138453A1 (en) 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
US6835536B2 (en) * 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
JP2003171463A (ja) 2001-12-06 2003-06-20 Chisso Corp ポリリジン及びその製造法
CA2443472A1 (en) 2002-02-07 2003-08-14 Ophtecs Corporation Liquid formulation for contact lenses
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
WO2005005436A2 (en) 2003-07-11 2005-01-20 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2005018701A1 (en) 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
CA2550872C (en) 2003-12-30 2016-05-03 Stig Bengmark Surface protection of exposed biological tissues
EP1722819B1 (en) 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
DK1927597T3 (en) 2004-08-18 2017-02-13 Novabiotics Ltd ANTIBACTERIAL PEPTIDES
KR20080023218A (ko) 2005-06-06 2008-03-12 노보자임스 에이/에스 항균성을 가진 폴리펩티드 및 그것을 코딩하는폴리뉴클레오티드
US20080139450A1 (en) 2005-07-01 2008-06-12 Srinivasa Madhyastha Antimicrobial Compositions and Uses Thereof
US20070190110A1 (en) 2006-02-10 2007-08-16 Pameijer Cornelis H Agents and devices for providing blood clotting functions to wounds
KR101475447B1 (ko) 2006-12-01 2014-12-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 자기-조립 블록 코폴리머의 베시클 그리고 그것의 제조 및 사용 방법
JP2010531189A (ja) 2007-06-25 2010-09-24 リポペプチド・アクチエボラーグ 新しい医療用製品
US20090081249A1 (en) 2007-08-27 2009-03-26 Massachusetts Institute Of Technology Bi-Functional Polymer-Attached Inhibitors of Influenza Virus
US20110098344A1 (en) 2008-06-19 2011-04-28 Nippon Shinyaku Co., Ltd. Drug carrier
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
CA2750340C (en) 2009-01-23 2017-09-19 Kane Biotech Inc. Biofilm-removing antimicrobial compositions and uses thereof
GB0905451D0 (en) 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
DK2563916T3 (en) 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
EP2608800B1 (en) 2010-08-23 2017-01-18 The Regents of The University of California Compositions and uses of materials with high antimicrobial activity and low toxicity
CN103370087A (zh) * 2011-01-19 2013-10-23 目立康株式会社 隐形眼镜用液体制剂
US9781949B2 (en) 2011-03-31 2017-10-10 The University Of Massachusetts Antimicrobial delivery systems, methods of manufacture, and methods of use thereof
MX344635B (es) 2012-03-23 2017-01-04 Amicrobe Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
DE102014101663A1 (de) 2014-02-11 2015-08-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthetische artifizielle Peptide mit antimikrobieller Wirkung
EP3194422B1 (en) 2014-09-19 2020-04-29 Tensive Controls, Inc. Anti-microbial peptides
AU2015338969B2 (en) * 2014-10-30 2020-08-27 Biomet Manufacturing, Llc Methods of preventing surgical site infections
JP2016113373A (ja) * 2014-12-11 2016-06-23 エスポ化学株式会社 抗菌性、抗ウイルス性を有する水溶性組成物
CN110740744A (zh) 2017-04-06 2020-01-31 艾麦克罗比公司 性能和安全性增强的局部施用的抗微生物剂的组合物和应用
WO2019169324A1 (en) 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions

Also Published As

Publication number Publication date
US20260041728A1 (en) 2026-02-12
AU2023202283B2 (en) 2026-06-25
JP2020513016A (ja) 2020-04-30
JP7656643B2 (ja) 2025-04-03
WO2018187617A8 (en) 2019-10-17
EP3606543A1 (en) 2020-02-12
KR20200018400A (ko) 2020-02-19
US11285189B2 (en) 2022-03-29
US20210100867A1 (en) 2021-04-08
AU2023202283A1 (en) 2023-05-11
BR112019020781A2 (pt) 2020-04-28
RU2019133628A (ru) 2021-05-06
CN110740744A (zh) 2020-01-31
CA3058901C (en) 2025-05-06
EP3606543A4 (en) 2020-12-16
MX2022007904A (es) 2022-07-21
JP2025090864A (ja) 2025-06-17
US12268722B2 (en) 2025-04-08
SG11201909016TA (en) 2019-10-30
KR20240135875A (ko) 2024-09-12
CA3058901A1 (en) 2018-10-11
JP2023054375A (ja) 2023-04-13
RU2019133628A3 (cg-RX-API-DMAC7.html) 2021-07-14
US20230017994A1 (en) 2023-01-19
WO2018187617A1 (en) 2018-10-11
MX393548B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
US12268722B2 (en) Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
Nguyen et al. Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment
Almeida et al. Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): Main features and their applications in topical and transdermal administration of drugs
JP5203472B2 (ja) キサンタンガムを含む再上皮化医薬組成物
CN1215988A (zh) 在眼中停留时间长的眼药组合物
Das et al. The gamut of perspectives, challenges, and recent trends for in situ hydrogels: A smart ophthalmic drug delivery vehicle
WO2023019143A1 (en) Films formed from self-assembling peptide hydrogels
CN105744929A (zh) 由透明质酸制成的连续释放组合物及其治疗应用
Mao et al. A review on in situ gels as polymer drug carriers in the treatment of periodontitis
Nnamani et al. Evaluation of Hydrogels Based on Poloxamer 407 and Polyacrylic Acids for Enhanced Topical Activity of Gentamicin against Susceptible Infections.
CZ20032771A3 (cs) Farmaceutická kompozice na bázi makrolidů pro lokální podání v očním lékařství
Sha et al. In situ gels: The next new frontier in ophthalmic drug delivery system
CN109568645B (zh) 一种复合生长因子促修复凝胶及其制备方法与应用
RU2824578C2 (ru) Композиции и применения антимикробных средств для местного применения с улучшенными характеристиками и безопасностью
WO2019084197A1 (en) DEGRADABLE HYDROGELS SENSITIVE TO TEMPERATURE
P Venkatesh et al. In situ gels based drug delivery systems
WO2021207164A1 (en) Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
TW201628657A (zh) 眼用組成物
EP4356929A1 (en) Antifibrotic formulation for ophthalmic treatment
WO2026060306A1 (en) Compositions and uses of locally applied synthetic cationic and hydrophobic amino acid block copolymers, for prevention and treatment of bacterial and fungal infections
US8679511B2 (en) In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
JP2023509400A (ja) 微粒子を含有する医薬組成物の製造方法
MXPA06004865A (en) Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOSITIONS AND USES OF LOCALLY-APPLIED ANTIMICROBIAL SYNTHETIC CATIONIC POLYPEPTIDE(S) WITH ENHANCED PERFORMANCE AND SAFETY

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted